JAMA Network
About The Study: In this large cohort of adults with overweight or obesity without diabetes, fewer than 1 in 4 patients remained on any glucagon-like peptide-1 receptor agonist (GLP-1RA) after 12 months. Switching between GLP-1RA agents was common and may reflect active therapy management rather than nonengagement, particularly as new formulations and weight management agents emerge.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
